Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
IPXELOX will investigate the safety, tolerability, and antitumor activity of intraperitoneal
paclitaxel in combination with chemotherapy in patients with advanced gastric cancer with
peritoneal metastasis.
Study hypotheses: Intraperitoneal paclitaxel administered to subjects at the recommended
phase 2 dose will show manageable safety and tolerability and anti-tumor efficacy with
systemic capecitabine and oxaliplatin in advanced gastric cancer with peritoneal metastasis.